Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GPR6 | P46095 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14704932 | 0.81 | JAK2 (0.39) | KDM4EALDH1A1GAAHPGDSMYD3 | |
| SCHEMBL10257621 | 0.81 | JAK2 (0.39) | KDM4EALDH1A1GAAHPGDSMYD3 | |
| SCHEMBL19669670 | 0.81 | SMYD3 (0.38) | SMYD3 | |
| SCHEMBL10257797 | 0.76 | JAK2 (0.38) | KDM4EALDH1A1GAAHPGDSMYD3 | |
| SCHEMBL20857176 | 0.75 | SMYD3 (0.34) | ALDH1A1HPGDSMYD3 | |
| SCHEMBL19184095 | 0.75 | MCHR1 (0.33) | — | |
| SCHEMBL27103194 | 0.74 | JAK2 (0.39) | KDM4EALDH1A1GAAHPGD | |
| SCHEMBL618558 | 0.74 | HPGD (0.39) | KDM4EALDH1A1GAAHPGDSMYD3 | |
| SCHEMBL21149068 | 0.73 | TP53 (0.38) | SMYD3 | |
| SCHEMBL10257497 | 0.72 | IKBKB (0.43) | SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10244779-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | SENOMYX, INC. (US) | 2019-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10244779-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | TFEB, TREH, SLC2A8 | KDM4E 476/4885ALDH1A1 3324/4885GAA 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.